Compare Abbott Laboratories (ABT) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs General Mills, Inc. — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while General Mills, Inc. trades at $36.56 (market cap $19.80B). The key difference: Abbott Laboratories is far larger — about 8.4× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.58%). Which is the better fit depends on your goals.
| ABT | GIS | |
|---|---|---|
Market Cap | $166.94B | $19.80B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $51.84 |
52-Week Low | $82.57 | $32.17 |
Enterprise Value | $193.69B | $33.29B |
Dividend Yield | 2.63% | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
General Mills (GIS) trades at $37.10, down 1.25% on the day, with a bullish technical signal from moving averages and a neutral RSI near 58. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. The company maintains a dividend of $0.61 per share and is implementing cost-saving initiatives targeting $3B by 2030 to counter margin pressures from private-label competition.
Outlook: GIS presents a value opportunity with a low P/E of 9.23, but faces headwinds from sluggish sales and negative net income margin. Risks include consumer spending shifts and high debt levels. Analyst consensus is cautious with a hold-heavy rating and a $36.14 price target slightly below current levels, suggesting limited near-term upside without stronger earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
